Prostacyclin receptor stimulation facilitates detection of human platelet P2Y12 receptor inhibition by the PFA-100® system

Platelets

Volumn 21, Issue 2, 2010, Pages 112-116

  Kobsar, Anna L ^a   Koessler, Juergen ^a   Rajkovic, Mirjana S ^a,b   Brunner, Kirsten P ^a   Steigerwald, Udo ^a   Walter, Ulrich ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Antiplatelet treatment; Cangrelor; Clopidogrel; Platelet reactivity index (VASP PRI)

Indexed keywords

CANGRELOR; CLOPIDOGREL; COLLAGEN; ILOPROST; PROSTACYCLIN RECEPTOR; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ANALYZER; ARTICLE; ASSAY; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MALE; NORMAL HUMAN; OPTIMAL DRUG DOSE; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RELIABILITY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STIMULATION; THROMBOCYTE; TIME;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADULT; BLOOD PLATELETS; CELL ADHESION MOLECULES; FEMALE; FLOW CYTOMETRY; HUMANS; ILOPROST; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, EPOPROSTENOL; RECEPTORS, PURINERGIC P2; TICLOPIDINE; YOUNG ADULT;

EID: 77149156610     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537100903440937     Document Type: Article

References (16)

1. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:273-282.
2. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
3. Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19:2007-2011.
4. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82: 1145-1152.
5. Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, Lengenfelder B, Walter U, Eigenthaler M. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004;92:1201-1206.
6. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005;51:957-965.
7. Michelson AD. P2Y12 antagonism: Promises and challenges. Arterioscler Thromb Vasc Biol 2008;28:33-38.
8. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5 Suppl 1:230-237.
9. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92. (Pubitemid 41647119)
10. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51: 1404-1411.
11. Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006;96:767-773.
12. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008;99:215-222.
13. Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, Walter U, Munzel T. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Atherosclerosis 2008;196:689-695.
14. Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists-in vitro experience. Clin Chem Lab Med 2004;42:25-29.
15. Pidcock M, Harrison P. Can the PFA-100 be modified to detect P2Y12 inhibition? J Thromb Haemost 2006;4: 1424-1426.
16. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4: 312-319.